ScaleReady Awards G-Rex® Grant to Support Cell-Easy as a European Hub for G-Rex®-Based Manufacturing
Toulouse, 2026 June 11th
ScaleReady, a joint venture between Wilson Wolf and Bio-Techne and provider of scalable cell culture technologies, has awarded a G-Rex® Grant to Cell-Easy to support the development of a European hub for G-Rex®-based cell therapy manufacturing within the French CDMO.
G-Rex® is widely recognized as a leading platform for scalable cell culture and is broadly adopted by cell therapy developers worldwide. When properly implemented and optimized, the technology can deliver strong performance in both cell quality and yield. Achieving these outcomes, however, requires a solid understanding of the platform and careful control of key process parameters—capabilities that developers increasingly seek from experienced CDMO partners.
“For biotech companies developing cell therapies on G-Rex®, working with a CDMO that understands the platform well can make a significant difference,” said Josh Ludwig, Global Commercial Director at ScaleReady. “Process efficiency, reproducibility, and cost control depend on the manufacturer’s ability to optimize multiple parameters. Through this grant, we aim to further strengthen Cell-Easy’s expertise and establish them as an important European partner for developers working with G-Rex® technology.”
The grant supports a comprehensive project focused on engineered T-cell therapies, applying a Quality by Design approach. Cell-Easy will work on optimizing key process parameters — including cell seeding density, culture conditions, and transduction strategies — before confirming process robustness through scale-up studies performed both at Cell-Easy’s facility and at ScaleReady’s CDMO site in the United States: CellReady (Houston, Texas).
For developers, working with a CDMO experienced in a given technology can translate into faster technology transfer, more predictable development timelines, and manufacturing processes that are better optimized from the outset. By generating validated workflows and deeper process understanding, the collaboration aims to help developers reduce development risk and facilitate the transition from early-stage development to GMP manufacturing.
Cell-Easy brings prior experience with G-Rex® platforms and a science-driven approach to process development. Through this collaboration with ScaleReady, the company will further expand its capabilities and contribute to making optimized G-Rex®-based manufacturing more accessible to cell therapy developers across Europe.
ScaleReady’s G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady’s growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more.
In 2026, ScaleReady has launched the G-Rex Grant Tour. This 12-part event series around the United States will rally, foster, and invest in the local cell & gene therapy community, promote transparency and collaboration among like-minded individuals and organizations working towards a common goal, catalyze scientific and clinical progress through a shared sense of duty to patients, and spotlight the breadth of innovative CGT approaches being powered by G-Rex. All sponsorship dollars raised will go to support the Emily Whitehead Foundation.
Follow the links for more information about the G-Rex® Grant Program and the G-Rex® Grant Tour.
About ScaleReady
ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world’s most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady’s expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf’s mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at:, LinkedIn, X or YouTube.
About CellReady LLC
CellReady is the world’s first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady’s mission is to create hope for cancer patients, one G-Rex® process at a time.
About Cell-Easy
Cell-Easy is a global CDMO with a dedicated focus on advanced cell therapies. Established in 2017, Cell-Easy’s commitment extends beyond development and manufacturing; it also places a strong emphasis on regulatory and CMC requirements.
Cell-Easy is a science-driven CDMO specialized in advanced Cell Therapies. Cell-Easy offers a broad range of Services, including Process and Analytical development, GMP manufacturing and CMC/Regulatory support for global Biotechs & Pharmas. The scientific team and QbD approach enable seamless technology transfer and development for cell-based therapies in the fields of oncology, autoimmune diseases and regenerative medicine (T cells, NK cells, Macrophages, MSCs, HSCs and any immortalized cell lines). In addition to its role as a conventional CDMO, Cell-Easy provides a range of added-value services, including: i) access to patients through an extensive network of national clinicians, ii) access to the human biological materials required to produce cell therapies, and iii) comprehensive CMC and regulatory support to accelerate the market approval of these cutting-edge therapies.
Explore our services at https://www.cell-easy.com and don’t hesitate to contact us at info@cell-easy.com